Skip to main content

prmt5 inhibitor azd3470

Generic: PRMT5 Inhibitor AZD3470

prmt5 inhibitor azd3470: 2 clinical trials tracked.

prmt5 inhibitor azd3470 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about prmt5 inhibitor azd3470, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (2)

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies

NCT06137144·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

InterventionalRandomizedopen161 targetStarted 2024-01Completion 2029-0537 sites · Australia, China, France, Germany…AstraZeneca

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient

NCT06130553·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents

Interventionalopen334 targetStarted 2024-01Completion 2028-1221 sites · Australia, China, France, Japan…AstraZeneca